An additional US$11 million has been committed to developing diagnostics and drugs for neglected tropical diseases.
The US$3.2 billion transaction will form the largest pharmaceutical company in India and the fifth largest specialty generics manufacturer in the world.
Two of Japan's largest pharmaceutical firms will share their drug libraries, making 400,000 compounds available for high throughput sequencing.
The Global Health Innovative Technology Fund, a new public-private partnership, is taking Japanese R&D to the global fight against infectious disease.
Daiichi Sankyo and NGM Biopharmaceuticals will collaborate to discover and develop novel therapeutics that modulate beta-cell regeneration for the treatment of diabetes.
GlaxoSmithKline and Daiichi Sankyo Co. Ltd. have signed a joint venture agreement to form a vaccines company in Japan.
Professor Hiroyuki Mano of Jichi Medical University has won the Ninth Takamine Memorial Daiichi Sankyo Prize.
Daiichi Sankyo Co. has received its first marketing approval for LIXIANA® tablets by the Ministry of Health, Labor and Welfare in Japan.